For how we live.
Nine countries have launched lenacapavir for HIV prevention, with roughly 66,000 people newly started on it. In at least two countries, demand has already outrun the available doses.
Years of observational data suggested 4CMenB cut gonorrhea risk by a third or more. A placebo-controlled trial in 654 people at high risk found essentially no effect at all.
The estimate covers 2000 to 2023 and 108 countries. It is a counterfactual model, not a measured saving, and it lands as the US and other donors debate cutting the disease-specific funding it credits.
The Lancet Global Health paper that produced this month's headline number also produced a larger one: 22.6 million additional deaths by 2030 if defunding deepens. The distinction matters more than the figure.